Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELOBiotechnology
-$0.04 today
- Market cap
- $50.84M
- Beta
- -0.24
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.27
Volume 0.17M
Average 0.13M
TELO Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Telomir Pharmaceuticals, Inc. Common StockNASDAQ: TELO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $990.95K (cash outflow) fell 54.5% year over year, behind the -26.0% change in trailing-twelve-month net income. Sequentially, it fell 51.9% from the prior quarter. Over 3 fiscal years it compounded at +130.2% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -54.5% toward the trailing-twelve-month pace of -26.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (10.41M) USD
- Year-over-year change
- +37.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10.41M) | +37.0% |
| FY2024 | 2024-12-31 | (16.53M) | -26.5% |
| FY2023 | 2023-12-31 | (13.07M) | -1430.4% |
| FY2022 | 2022-12-31 | (854.15K) | -518.4% |
| FY2021 | 2021-12-31 | (138.13K) | — |
Net Income vs competitors
How TELO compares with its peers on the latest reported figures
- TELO's LTM Mar 2026 net income of $9.22M is the 5th largest of the 6 companies compared; the peer median is $19.06M.
- Its year-over-year change of -26.0% is the lowest of 6, against a peer median of +110.8%.
- Over three fiscal years its annual growth of +130.2% compares with a peer median of -28.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $194.97M | +211.8% | +5.9% | 129.0% | |
| LTM Mar 2026 | $107.79M | +391.1% | -58.2% | — | |
| LTM Mar 2026 | $19.06M | +36.2% | -28.9% | — | |
| LTM Mar 2026 | $12.72M | +12.6% | -31.8% | 899.5% | |
| LTM Mar 2026 | $9.22M | -26.0% | +130.2% | — | |
| LTM Mar 2026 | $4.41M | +110.8% | +18.9% | — | |
| Peer median (excluding TELO) | $19.06M | +110.8% | -28.9% | 514.2% | |
Competitors are the stored peer set for TELO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (138.13K) | (854.15K) | (13.07M) | (16.53M) | (10.41M) |
| Depreciation & Amortization | 0 | 0 | 0 | 4.34M | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 6.87M | 5.29M |
| Change in Working Capital | 18.74K | 385.49K | 113.84K | 126.47K | 594.69K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 18.74K | 0 | 114.56K | 183.63K | (50.77K) |
| Other Working Capital | 18.74K | 385.49K | (713) | (57.16K) | 645.46K |
| Other Non-Cash Items | 0 | 385.49K | 9.1M | 130K | 840K |
| Operating Cash Flow | (119.4K) | (468.66K) | (3.86M) | (5.07M) | (3.69M) |
| Capital Expenditures | (4) | 0 | (4) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 462.39K | 3.17M | (101K) | 0 |
| Common Stock Issued | 0 | 0 | 1M | 6.83M | 9.55M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 119.4K | 7.69K | (310.38K) | (396.65K) | 155.52K |
| Financing Cash Flow | 119.4K | 470.08K | 3.86M | 6.34M | 9.71M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 0 | 1.42K | (188) | 1.26M | 6.02M |
| Free Cash Flow | (119.4K) | (468.66K) | (3.86M) | (5.07M) | (3.69M) |
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELO
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.